Genmab A/S (OTCMKTS:GNMSF) Short Interest Update

Genmab A/S (OTCMKTS:GNMSF) saw a significant drop in short interest in the month of August. As of August 15th, there was short interest totaling 22,800 shares, adropof25.2% from the July 31st total of 30,500 shares. Based on an average daily volume of 1,800 shares, the short-interest ratio is currently 12.7 days. Based on an average daily volume of 1,800 shares, the short-interest ratio is currently 12.7 days.

Genmab A/S Trading Up 1.1%

Shares of OTCMKTS:GNMSF opened at $277.60 on Tuesday. The firm has a market cap of $18.34 billion, a PE ratio of 13.94 and a beta of 0.90. The company has a fifty day simple moving average of $226.49 and a 200 day simple moving average of $212.70. Genmab A/S has a 12-month low of $170.00 and a 12-month high of $279.52.

Genmab A/S (OTCMKTS:GNMSF) last released its quarterly earnings data on Thursday, August 7th. The company reported $5.42 EPS for the quarter, topping analysts’ consensus estimates of $3.99 by $1.43. The firm had revenue of $925.00 million during the quarter, compared to the consensus estimate of $949.06 million. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.